Bispecific CD3-engaging antibodies may have advantages over other T cell therapies because they can engage pre-existing polyclonal CD8- and CD4-positive T cells, do not require antigen presentation by MHC molecules, and bind to surface antigens on cancer cells that may be more homogenously expressed than MHC/peptide antigens. Here, CD8A is linked to cancer.